SCHEMBL2118378

SCHEMBL2118378

O=S(=O)(c1ccc(Cl)cc1)N(Cc1ccccc1)c1ccccn1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.82
SMN1; SMN2 Q16637 1/20 0.82
KDM4E B2RXH2 3/20 0.65
HPGD P15428 2/20 0.65
HSD17B10 Q99714 1/20 0.65
PKM P14618 1/20 0.59
CXCR3 P49682 2/20 0.58
NR3C1 P04150 1/20 0.56
PGR P06401 1/20 0.56
TRPM8 Q7Z2W7 3/20 0.54
CNR2 P34972 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
NPC1 O15118 1/20 0.50
CNR1 P21554 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TAS2R14 Q9NYV8 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120000 0.90 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL2116993 0.86 ALDH1A1 (0.82) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL2117002 0.86 ALDH1A1 (0.82) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL2122260 0.83 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL2121920 0.83 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL2119787 0.82 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL2117044 0.79 GAA (0.71) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL13571459 0.76 PKM (0.67) ALDH1A1SMN1; SMN2PKMNR3C1PGR
SCHEMBL13065193 0.75 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL2119077 0.75 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 ALDH1A1 1996/4885SMN1; SMN2 1501/4885KDM4E 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.